2024 SABCS
2024年圣安东尼奥乳腺癌学术研讨会（SABCS）将于2024年12月10至13日在美国德克萨斯州圣安东尼奥举行。SABCS官网已披露入选本次大会的摘要标题，医脉通小编为您汇总大会相关信息，精选中国专家报告内容，往期传送：2024 SABCS摘要标题来啦！一起来领略中国专家风采吧~
本期将为读者带来中国专家Poster Session 1（壁报展示1）部分，医脉通与您携手同行，共同探索前沿医学成果。
医脉通小编与您相约圣安东尼奥Henry B. Gonzalez会议中心（地址：900 E. Market Street, San Antonio, TX 78205 USA），为您带来一手资讯！敬请关注医脉通乳腺肿瘤，共享乳腺癌领域最新进展！
Henry B. Gonzalez Convention Center
中国专家壁报展示专场日期及时间一览，跟随医脉通，共享学术盛宴！
2024 SABCS Poster Session时间轴
Poster Session 1
壁报展示1
当地时间：2024/12/11 12:30-14:00
北京时间：2024/12/12 2:30-4:00
位置：Halls 2-3
01
P1-01-04
EPLIN and EPLIN responsive protein APOC3 in breast cancer
EPLIN和EPLIN应答蛋白APOC3在乳腺癌中的应用
报告人：Cai Wang
02
P1-02-12
Prospective phase II study on the efficacy and safety of hetrombopag for the treatment of cancer therapy-induced thrombocytopenia in patients with breast cancer
海曲泊帕治疗乳腺癌患者癌症治疗诱导的血小板减少症的疗效和安全性的前瞻性II期研究
报告人：Hanfang Jiang
03
P1-02-18
Cancer-Associated Fibroblast-Mediated Suppression of T Cell Activity as a mechanism of Resistance to Immunoradiotherapy in Breast Cancer
癌症相关成纤维细胞介导的T细胞活性抑制是乳腺癌免疫放疗耐药的机制
报告人：Rongrong Wu
04
P1-04-04
evelopment and validation of a nomogram for axillary lymph node metastasis risk in breast cancer
乳腺癌腋窝淋巴结转移风险列线图的开发和验证
报告人：Xiaoyun Mao
05
P1-04-12
Optimizing Tolerability of Pyrotinib in HER2-Positive Early Stage High-Risk Breast Cancer: A Multicenter, Randomized, Three Cohort Study
优化吡咯替尼在HER2阳性早期高危乳腺癌中的耐受性：一项多中心、随机、三队列研究
报告人：Qiao Cheng
06
P1-04-22
Loss of SMAD4 Drives Breast Cancer Invasion and Metastasis through E2F1-Mediated Activation of the PEG10-ERK Axis
SMAD4缺失通过E2F1介导的PEG10-ERK轴激活驱动乳腺癌侵袭和转移
报告人：Dan Shu
07
P1-04-25
Fast and accurate detection of tumor-immune cell interactions with deep learning
通过深度学习快速准确地检测肿瘤-免疫细胞相互作用
报告人：Huiping Liu
08
P1-05-07
Expression of ATP6AP2 in clinical breast cancer and the prognostic and therapeutic value in ERBB2 subtype of breast cancer
ATP6AP2在临床乳腺癌中的表达及其在ERBB2亚型乳腺癌中的预后和治疗价值
报告人：Jia Tong
09
P1-05-24
Biomarkers and Spatial Determinants of SHR-A1811 Efficacy in Neoadjuvant Treatment for HER2-Positive Breast Cancer
SHR-A1811在HER2阳性乳腺癌新辅助治疗中疗效的生物标志物和空间决定因素
报告人：Zhi-Ming Shao
10
P1-05-27
Analytical comparison of tissue-based next-generation sequencing assays for the detection of PIK3CA, AKT1, and PTEN tumor alterations in breast cancer
基于组织的下一代测序检测试剂盒检测乳腺癌中PIK3CA、AKT1和PTEN肿瘤改变的分析比较
报告人：Xiaodun Li
11
P1-06-04
Psychological stress and its correlations to patients with acute lymphedema after breast cancer surgery
心理应激及其与乳腺癌术后急性淋巴水肿患者的相关性
报告人：Li-Chen Tang
12
P1-06-06
Oral cyclophosphamide-induced hemorrhagic cystitis from metronomic Cyclophosphamide/Methotrexate/5-Fluorouracil for treatment of synchronous bilateral breast cancer – A case report
节律型环磷酰胺/甲氨蝶呤/5-氟尿嘧啶引起的口服环磷酰胺诱导的出血性膀胱炎治疗同步性双侧乳腺癌——病例报告
报告人：Jina Yun
13
P1-06-07
APOE4 impairs the cardiac stress response to doxorubicin through defective M2 macrophage activation and tissue repair transcription pathways
APOE4通过M2巨噬细胞活化和组织修复转录途径缺陷损害心脏对阿霉素的应激反应
报告人：Guannan Wang
14
P1-06-24
Single-cell RNA sequencing reveals the role of HSPA1B+ immune cells in breast cancer microenvironment remodeling during neoadjuvant chemotherapy
单细胞RNA测序揭示了HSPA1B+免疫细胞在新辅助化疗期间乳腺癌微环境重塑中的作用
报告人：Zihan Zhai
15
P1-06-29
Targeting NRP1 reduces triple-negative breast cancer lung metastasis and improves immunotherapy efficacy
靶向NRP1可减少三阴性乳腺癌肺转移并提高免疫治疗效果
报告人：Zhuxi Duan
16
P1-07-20
Mechanism of miR-221-3p/PARP1 regulating the progression of triple-negative breast cancer through the NF-κB pathway
miR-221-3p/PARP1通过NF-κB通路调控三阴性乳腺癌进展的机制
报告人：Qianqian Lei
17
P1-07-21
Efficacy of CDK4/6 Inhibitor Abemaciclib in Metastatic Triple-Negative Breast Cancer
CDK4/6抑制剂阿贝西利在转移性三阴性乳腺癌中的疗效
报告人：Chuling Zhuang
18
P1-07-25
E3 ubiquitin-protein ligase RNF40 promotes triple-negative breast cancer progression and metastasis by promoting TRIM28 expression and stabilizing TWIST1 protein
E3泛素蛋白连接酶RNF40通过促进TRIM28表达和稳定TWIST1蛋白促进三阴性乳腺癌进展和转移
报告人：Junjiang Fu
19
P1-07-28
Real-World Study on Efficacy and Safety of SG Alone and Combined with Immunotherapy in Metastatic Triple Negative Breast Cancer Patients
单独使用SG和联合免疫疗法治疗转移性三阴性乳腺癌患者疗效和安全性的真实世界研究
报告人：Jianli Zhao
20
P1-08-02
HIF-1-dependent expression of integrin β3 incorporated into extracellular vesicles promotes metastasis of breast cancer cells to the brain
整合到细胞外囊泡中的HIF-1依赖性整合素β3表达促进乳腺癌细胞向大脑转移
报告人：Yongkang Yang
21
P1-08-05
The mechanism of FOXO3a in coping with oxidative stress to promote TNBC progression
FOXO3a应对氧化应激促进TNBC进展的机制
报告人：Manqing Cao
22
P1-08-14
The occurrence of immune-related adverse events and overall survival among breast cancer patients receiving pembrolizumab
接受帕博利珠单抗治疗的乳腺癌患者免疫相关不良事件的发生率和总生存期
报告人：Cho-Han Chiang
23
P1-08-21
Synchronous female breast cancer and follicular lymphoma in a single patient: A case report
一例同时患乳腺癌和滤泡性淋巴瘤的女性病例报告
报告人：Zijun Zhao
24
P1-08-22
T-DXd treatment of microangiopathic hemolytic anemia associated with HER2-low breast cancer: A case report
T-DXd治疗HER2低表达乳腺癌相关微血管病性溶血性贫血的病例报告
报告人：Mao Ding
25
P1-09-05
Simultaneous 3D Mapping of RNA and Protein to Advance Personalized Medicine in Breast Cancer
RNA和蛋白质的同步3D映射以推进乳腺癌的个性化医疗
报告人：Yue Li
26
P1-09-11
Machine Learning based analysis in chemotherapy resistant triple negative breast cancer
基于机器学习的化疗耐药三阴性乳腺癌分析
报告人：Dongling Wu
27
P1-09-24
Cancer cell-derived exosomal miR-20a-5p inhibits CD8+ T-cell function and confers anti-programmed cell death 1 therapy resistance in triple-negative breast cancer
癌细胞来源的外泌体miR-20a-5p抑制CD8+T细胞功能，并在三阴性乳腺癌中赋予抗程序性细胞死亡1治疗耐药性
报告人：XIANGDONG BAI
28
P1-10-17
HER2+ breast cancer diagnosed in the 2nd trimester of pregnancy
一例在妊娠中期确诊的HER2+乳腺癌
报告人：Shiliang Zhang
29
P1-11-01
Immune Infiltration Correlates with Transcriptomic Subtypes in Primary ER+ Invasive Lobular Breast Cancer
免疫浸润与原发性ER+浸润性小叶乳腺癌中的转录组亚型相关
报告人：Fangyuan Chen
30
P1-11-07
Associations between Breast Cancer Index Classifications and MSK-IMPACT Genomic Profiles in HR+/HER2- Breast Cancer
HR+/HER2-乳腺癌中乳腺癌指数分类与MSK-IMPACT基因组图谱之间的关联
报告人：Hong Zhang
31
P1-11-11
Pathological Complete Response and Survival Outcomes of Single Hormone Receptor-Positive/HER2-Negative Breast Cancer after Neoadjuvant Treatment and Further analysis of its Intrinsic Biological Features and Immune Landscape
单激素受体阳性/HER2阴性乳腺癌新辅助治疗后的病理完全缓解和生存结果，并进一步分析其内在生物学特征和免疫景观
报告人：Lei Ji
32
P1-11-12
Early-stage HR+/HER2- breast cancer patients under 50 years old with a low-risk identified by the 70-gene signature (MammaPrintTM) could benefit from ovarian function suppression: A real-world study in China.
50岁以下的早期HR+/HER2-乳腺癌患者，通过70基因特征（MammaPrintTM）确定的低风险患者可能受益于卵巢功能抑制：一项在中国的真实世界研究
报告人：Weijuan Jia
33
P1-11-13
Development and Validation of a Deep Learning Model for HR+/HER2- Early-stage Breast Cancer Recurrence Prediction (HERPAI) using Conventional Clinical and Pathological Data: A Real-world Study in Chinese Population
使用常规临床和病理数据开发和验证HR+/HER2-早期乳腺癌复发预测（HERPAI）深度学习模型：中国人群的真实世界研究
报告人：Ruixin Pan
34
P1-12-03
Clinical Efficacy and Outcomes of Astragalus Polysaccharides (PG2) toward Cancer-related Fatigue of Advanced Breast Cancer Patients
黄芪多糖（PG2）对晚期乳腺癌患者癌症相关疲劳的临床疗效和结果
报告人：Kun-Ming Rau
35
P1-12-09
Real-world prescribing patterns and outcomes of CDK4/6 inhibitors in elderly patients with metastatic HR+/HER2- breast cancer
CDK4/6抑制剂在老年转移性HR+/HER2-乳腺癌患者中的真实世界处方模式和结果
报告人：Xiao-Wei Tan
36
P1-12-26
Clinical Case Vignette - Molecular PET Imaging to Guide Selection for Endocrine Therapy in Estrogen-Receptor Positive Metastatic Breast Cancer
临床病例小插图-分子PET成像指导雌激素受体阳性转移性乳腺癌内分泌治疗的选择
报告人：Wenhui Zhou
37
P1-12-27
Clinical Case Vignette: Estrogen Receptor Targeting PET Imaging to Monitor Treatment Response to Endocrine Therapy in Lobular Breast Cancer
临床病例小插图：雌激素受体靶向PET成像监测小叶乳腺癌对内分泌治疗的治疗反应
报告人：Wenhui Zhou
备注：排名不分先后，按照摘要号进行排序。本文内容基于SABCS官网发布的信息整理，因目前壁报部分未公布报告者单位，信息可能有遗漏或错误，欢迎留言告知。
编辑：KIKI
审校：Uni/Ryland
排版：KIKI
执行：Squid
医脉通是专业的在线医生平台，“感知世界医学脉搏，助力中国临床决策”是平台的使命。医脉通旗下拥有「临床指南」「用药参考」「医学文献王」「医知源」「e研通」「e脉播」等系列产品，全面满足医学工作者临床决策、获取新知及提升科研效率等方面的需求。
本平台旨在为医疗卫生专业人士传递更多医学信息。本平台发布的内容，不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议。如该等信息被用于了解医学信息以外的目的，本平台不承担相关责任。本平台对发布的内容，并不代表同意其描述和观点。若涉及版权问题，烦请权利人与我们联系，我们将尽快处理。
